Hepatoma-specific Alpha-fetoprotein for Early Diagnosis of Liver Cancer
Author Information
Author(s): PJ Johnson, N Leung, P Cheng, C Welby, WT Leung, WY Lau, S Yu, S Ho
Primary Institution: The Chinese University of Hong Kong, Prince of Wales Hospital
Hypothesis
Can the 'hepatoma-specific' alpha-fetoprotein test improve early diagnosis of malignant changes in patients with chronic liver disease?
Conclusion
The 'hepatoma-specific' alpha-fetoprotein test significantly increases the positive predictive value for diagnosing hepatocellular carcinoma.
Supporting Evidence
- 19 out of 26 patients with the 'hepatoma-specific' band developed HCC during the study.
- The positive predictive value of the 'hepatoma-specific' AFP test was 73.1%, compared to 41.5% for total AFP.
- Ultrasound detected tumors at a median of 3.6 months after the AFP test was positive.
Takeaway
Doctors can use a special blood test to find liver cancer earlier in patients with liver disease, which can help save lives.
Methodology
The study analyzed serum alpha-fetoprotein levels in patients with chronic liver disease and followed them for up to 18 months to diagnose hepatocellular carcinoma.
Potential Biases
The results may not be generalizable due to the specific patient population and the study's design.
Limitations
The study did not assess the impact of the test on patient outcomes or the potential for false positives.
Participant Demographics
91% had hepatitis B virus-related liver disease; less than 10% had alcoholic liver disease.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website